Skip to content

Effects of Scalp Nerve Blocks on Systemic Inflammation

Effects of Scalp Nerve Blocks on Systemic Inflammation After Meningeoma Resection Surgery:a Prospective Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02939833
Enrollment
160
Registered
2016-10-20
Start date
2017-01-31
Completion date
2019-10-31
Last updated
2016-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meningiomas

Brief summary

Patients undergoing meningeoma resection surgery will be randomly assigned to two groups. One group will receive scalp nerve blocks with 0.5% ropivacaine, whereas the other group will receive scalp nerve blocks with 0.9% saline after anesthesia induction and before skull-pin insertion. Serum levels of TNF-α、IL-6 and IL-1β will be measured and compared at before surgery, 1h, 24h and 72h after surgery, respectively. VAS score, dosage of pain-control medicine and NRS score at the first three days after surgery, ratio of intracranial infection within 30d after surgery, and total hospitalization days and medical expenditure will also be recorded and compared between the two groups.

Interventions

PROCEDUREScalp Nerve Blocks With Ropivacaine
PROCEDUREScalp Nerve Blocks With Saline

Sponsors

RenJi Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* BMI 18-28 kg/m2 ASA Physical Status 1-2 diagnosed Meningeoma and will have selective Meningeoma Resection Surgery the incision will be conducted at the frontal, top or the temperal skull.

Exclusion criteria

* previous brain surgery severe systemic disease (heart, lung, kidney, or immune system) nerval or mental disorders a history of addiction to opioids allergic to ropivacaine infection at block site or severe systemic infection refuse to attend the trial

Design outcomes

Primary

MeasureTime frame
serum TNF-α level24 hour after surgery
serum IL-6 level24 hour after surgery
serum IL-1β level24 hour after surgery

Secondary

MeasureTime frame
VAS score24 hour after surgery
dosage of pain-control medicinewithin 72 hour after surgery
NRS score24 hour after surgery
serum TNF-α level1 hour after surgery
Hospitalization Daysup to 30 days
out of pocket expenditure for hospitalisationhospital discharge/up to 30 days
incidence of intracranial infectionwithin 30 days after surgery
serum IL-6 level1 hour after surgery
serum IL-1β level1 hour after surgery

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026